Teva Pharmaceutical Industries (TEVA) Earnings Analysis

Teva Pharmaceutical Industries (TEVA) next reports earnings on 2026-07-29, consensus EPS 0.04772 USD. Last quarter (2026-04-29) it beat with EPS 0.53 USD vs 0.5 USD est (+6%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E 22.49.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TEVA next report earnings?

Next earnings date2026-07-29
Consensus EPS estimate0.04772 USD
Revenue estimate4.04B

TEVA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-290.53 USD0.5 USD+6%Beat
2026-01-280.96 USD0.65 USD+47.7%Beat
2025-01-290.71 USD0.69 USD+2.9%Beat

Beat rate: 3/3 (100%) over reported quarters with consensus data.

TEVA valuation and analyst view

Trailing P/E22.49
Trailing EPS1.362 USD
Price / book4.32
Dividend yield0.00%
Market cap35.40B
Analyst consensusBuy (21 buy / 21 hold / 4 sell)
Avg price target41.33 USD

Related research pages

Frequently asked questions

When is Teva Pharmaceutical Industries (TEVA)'s next earnings date?

Teva Pharmaceutical Industries is next scheduled to report on 2026-07-29, with a consensus EPS estimate of 0.04772 USD and revenue estimate of 4.04B.

Did TEVA beat earnings last quarter?

In its 2026-04-29 report, TEVA posted EPS of 0.53 USD versus a 0.5 USD estimate — a beat of 6%.

What is TEVA's earnings track record?

Over the last 3 reported quarters with consensus data, TEVA beat estimates 3 times (100%).

What is TEVA's current P/E ratio and EPS?

TEVA trades at a trailing P/E of 22.49 on trailing EPS of 1.3623837266435985 USD.

What do analysts rate TEVA?

Analyst consensus is "Buy" across 46 ratings (0 strong buy, 21 buy, 21 hold, 4 sell, 0 strong sell). Average 12-month price target: 41.33 USD.